The antimuscarinic compound atropine shows an antiherpesvirus effect as measured by the protection of the cell monolayer and the reduction of the formation of new infectious virus. Atropine at a concentration of 200 ,ug/ml blocks the production of new infectious herpes simplex virus-type 1 virions. At that concentration, it has almost no effect on cellular or viral protein synthesis even when atropine is present from the beginning of the infection. The glycosylation of viral proteins is almost totally blocked when atropine is added. Although the viral proteins are underglycosylated, the formation of new herpes simplex virus type 1 virions takes place. The virions formed in the presence of atropine are noninfectious, and their protein composition, as assessed by labeling with [35S]methionine, is similar to that of the control, except that they are not glycosylated.
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The search for new antiherpesvirus agents is widening at present. A number of compounds have been found in the last few years that show a selective inhibitory effect against herpesvirus functions, with moderate toxicity to cells (1, 2) . Most of those antiherpesvirus agents, such as acyclovir, bromovinyl deoxyuridine, and phosphonoformate (1, 2, 6) , act at the level of nucleic acid synthesis. The first two compounds show a high antiviral index, but since they are nucleoside analogs, they should be used with caution because of their potential mutagenic and teratogenic effects. New antiherpesvirus compounds acting on other viral functions need to be found. These new inhibitors in turn would be very useful to study in more detail the different steps of virus replication.
Looking for new compounds with antiherpesvirus activity, we found several that blocked virus replication selectively, with a low toxicity against culture cells (B. Alarc6n, J. C. Lacal, J. M. Fernandez-Sousa, and L. Carrasco. Antiviral Res., in press). Among those compounds, atropine was active not only against herpes simplex virus type 1 but also against other enveloped viruses (Alarc6n et al., in press). Yamazaki and Tagaya (11) . also found a similar antiviral effect of atropine and caffeine. Therefore, we decided to investigate the mechanism of action of atropine against HSV-1. The results are presented in this paper.
MATERIALS AND METHODS
Cells and viruses. HeLa cells were grown in Dulbecco modified Eagle medium (GIBCO Laboratories) supplemented with 10% newborn calf serum (GIBCO). HSV-1 strain KOS, kindly given to us by E. de Clerq (Leuven), was grown and titrated in African green monkey kidney cells (Vero cells).
Estimation of the cytopathic effect. Monolayers of HeLa cells were infected with HSV-1 or HSV-2 at a multiplicity of 0.5 PFU per cell in the presence or absence of atropine. At 48 h after incubation, the cell monolayer was examined under a phase-contrast microscope. The level of translation was also determined by 1 h of incubation with 1 ,XCi of
[35S]methionine (1, 100 Ci/mmol; Radiochemical Centre) per ml. The trichloroacetic acid-precipitable radioactivity was measured in an Intertechnique liquid scintillation counter.
Measurement of production of HSV-1 infectious units. Monolayers of HeLa cells were infected with HSV-1 at a multiplicity of 0.5 or 10 to analyze the reduction of infectious units in several cycles or in one cycle of replication. The infected cells were collected at 48 or 24 h postinfection, respectively. Atropine was added at the beginning of infection. Infected cells were disrupted by three freeze-thawing cycles. The infectious viruses produced were estimated by the standard plaque assay.
Analysis of proteins by polyacrylamide gel electrophoresis. After incubation of the cells in medium without methionine in the presence of 5 ,uCi of [35S]methionine per ml for the period of time indicated in each experiment, the medium was removed, and the cell monolayer was washed with 1 ml of saline phosphate buffer; the cells were dissolved in 0. 
RESULTS
Antiherpesvirus action of atropine. First, we analyzed the atropine protection of the cytopathic effect of HeLa cells induced by HSV-1 under different niultiplicities of infection (Fig. 1A) . Atropine protected the cytopathic effect less efficiently when high multiplicities of infection of HSV-1 were used, but if the virus had to replicate several times to induce the destruction of the cell monolayer, then atropine was effective at concentrations of 50 to 100 pug/ml. These concentrations agree well with the results previously reported on the inhibition of HSV-1 and influenza plaque units by atropine (11) . Figure 1B shows the level of protein synthesis in those cells incubated for 48 h in the presence of various concentrations of atropine. It is worth mentioning the relatively low toxicity of atropine in control cells, since not only did the cell monolayer remain intact, as observed under the microscope, (Fig. 1A) , but also the cells synthesized proteins at control levels even in the presence of 400 ,ug of atropine per ml. Besides, the cells which were infected with HSV-1 at low multiplicity synthesized proteins to almost control levels in the presence of 400 ptg of atropine per ml. In a similar experiment, this same effect was not observed with drugs like acyclovir or bromovinyl deoxyuridine, where the HSV-1-infected cells were morphologically protected, as observed under the microscope, but did not synthesize proteins after 48 h of treatment, even when the lowest multiplicity of infection of HSV-1 was used (Alarcon et al., in press). We have no obvious explanation for such behavior of the HSV-1-infected cells regarding the effects of acyclovir or bromovinyl deoxyuridine. One possibility is that since virus-infected cells are able to phosphorylate these compounds by means of the viral thymidine kinase, they might interphere with protein synthesis after long incubation periods. The inhibition of the formation of new infectious HSV-1 by atropine in a single-step or multiple-step growth cycle is shown in Fig. 1 , panels C and D, respectively. Atropine (100 pug/ml) diminished by 1 logarithm the production of HSV-1 PFU and some effect was already observed at 50 pLg/ml. On the other hand, at 200 pLg/ml, which is approximately equivalent to 1 mM atropine, there was a significant reduction in the formation of PFU. These concentrations compare well with the antiviral potency of other antiherpesvirus compounds which are not nucleoside analogs, such as phosphonoformate and 2-deoxyglucose (Alarc6n et al., in press).
Molecular mechanism of action. Once we determined the antiherpesvirus potency of atropine, the action of this compound on protein synthesis was investigated. We first examined the way different concentrations of atropine affected translation in HeLa cells that were either mock infected or infected with HSV-1 at a multiplicity of infection of 10. Figure 3A shows the autoradiogram of such a gel, where 200 ,ug of atropine per ml completely suppressed the glycosylation of viral proteins. Figure 3B shows the time course of [3H]glucosamine incorporation into HSV-1-infected cells in the presence or absence of 200 jig of atropine per ml. Remarkably enough, the peak of viral glycosylation was abolished by atropine. Since at those concentrations, atropine had no effect on translation, this suggests that atropine acts by inhibiting the glycosylation of viral proteins.
Analysis of HSV-1 virions formed in atropine-treated cells.
To test whether new virions were formed in atropine-treated cells, we infected HeLa cells with HSV-1 in the absence or presence of 200 ,ug of atropine per ml. The virions formed were collected and analyzed under the electron microscope. Table 1 shows that in the presence of 200 ,ug of atropine per ml there was lower reduction in the amount of virion particles formed than in the amount of infectious particles, and the percentages of the four morphological types obtained are similar both in control and in atropine-treated cells.
The infectivity of these virions was tested by adding the same volume of the HSV-1 preparation and analyzing the level of protein synthesis 18 h after its addition to new cultures of HeLa cells. Figure 4A shows that there was a ca. 1/50 to 1/100 reduction in the infectivity of the virions obtained from atropine-treated cells. These numbers are in good agreement with the reduction previously observed in Fig. 1 (Fig. 4B) . Some large proteins in the high-molecular-weight region started to appear at 10 to 12 h postinfection with virions obtained from atropine-treated cells, indicating that they are less infectious as compared with control virions.
Taken together, these results suggest that virions formed pLg/ml (data not shown). Neither were the related compounds, scopolamine [6, ,7p-epoxy-loH, 5otH-tropan-3o-ol-(-)tropate], eucatropine (o-hydroxybenzeneacetic acid, 1,2,2,6-tetramethyl-4-piperidinyl ester), and homatropine (lotH, 5aH-tropan-3ax-ol-mandelate), active at 400 ,ug/ml. It should be pointed out that atropine methylbromide is devoid of antiherpesvirus action, perhaps because atropine methylbromide is a charged molecule and cannot cross cellular membranes. DISCUSSION The finding that several natural compounds have antiherpesvirus activity (Alacaron et al., in press) has prompted us to investigate their mechanism of action in an attempt to provide new inhibitors of viral functions. Atropine is an inhibitor that shows significant antiherpesvirus action at 200 ,ug/ml. Although this concentration seems rather high, particularly when compared with the activity of some nucleoside analogs, such as acyclovir or bromovinyl deoxyuridine, it is lower than the amount necessary for phosphonoformate or 2-deoxyglucose to exert a comparable inhibitory effect on HSV-1 (Alarc6n et al., in press). It still remains to be tested whether atropine acts in the same way against HSV-1 infections in animals. Nevertheless, the main goal of our study was to clarify the step blocked by atropine during virus replication. According to our results, the action of atropine is clearly located at the level of protein glycosylation. The number of inhibitors discovered that block protein glycosylation has greatly increased during the last few years (4, 7, 8) . Some of them, like tunicamycin or 2-deoxy-D-glucose, block glycosylation at a very early step, when the activated sugar is donated to dolichol-phosphate, whereas others, like nojirimycin, bromoconduritol, or swainsonine, affect the trimming of the oligosaccharide attached to the protein. We do not yet know exactly which step in glycosylation is blocked by atropine, but it is most probably before the oligosaccharide is donated to the protein, because the viral proteins are not labeled in the presence of [3H]glucosamine.
Of particular interest is the finding that virions are assembled even though the viral proteins are not properly glycosylated, suggesting that glycosylation is not a prerequisite for this to take place. In fact, it has been reported recently that Therefore, glycosylation seems important to deliver the virjon particle or the virion genome in the cytoplasm or the nucleus. These findings are in good agreement with previous results from other laboratories. Thus, enveloped HSV-1 particles are formed in the presence of tunicamycin or 2-deoxy-D-glucose. These particles adsorb well to cells, but the transport of virus DNA to the nucleus is blocked, since they are so much less infectious (9, 10 
